Full-Time
IQVIA
10,001+ employees
Provides analytics and clinical research services
No salary listed
Mid, Senior
No H1B Sponsorship
Reading, UK + 1 more
More locations: Sant Cugat del Vallès, Barcelona, Spain
- Bachelor's degree in life sciences/healthcare (or clinically relevant degree) is required
- Advanced degree is strongly preferred
- ≥ 4 years of recent involvement in clinical research or drug development in an academic or industry environment spanning clinical activities in Phases I through IV of standard to high complexity
- ≥ 3 years of recent contribution to and accomplishment in all aspects of conducting clinical studies of standard to high complexity and priority (e.g., planning, executing, reporting and publishing) in a global/matrix environment in pharmaceutical industry or a contract research organization
- Expert knowledge of international standards (GCP/ICH), health authorities (FDA/EMA), local/National Health Authorities
- Excellent communicator and presenter (oral and written); ability to communicate at all levels
- Excellent organization and prioritization
- Strong negotiation and conflict resolution skills and enterprise mindset, demonstrated by ability to drive for aligned solutions
- Fluent English, oral and written
- Executes and delivers clinical studies; guides planning and decision making at study-level
- Acts as the CTT product owner with clear and focused duties and responsibilities per the agile ways of working
- Active member of a Clinical Operations community within the study leadership organization
- Promotes operational excellence in the development of global clinical study protocol(s), clinical study report(s), and other study-related documents
- Patient recruitment, clinical data, study documentation and study reports
- Efficient delivery of the protocol, ICF, Monitoring Plan, and CSR in quality and on time
- Cost effective management of study budget
- Proactive, iterative operational planning with effective contingencies and embedded risk management mindset in CTT
- Experience in managing people globally in a complex matrix environment preferred
- Management of virtual teams
- Proven ability and strong experience leading teams and building capabilities
- Experience in developing effective working relationships with internal and external stakeholders
IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their main offering, IQVIA Connected Intelligence™, utilizes big data and technology to deliver quick insights that help clients speed up the development and marketing of new medical treatments. This service is designed to improve healthcare outcomes by connecting various aspects of healthcare. IQVIA stands out from its competitors by focusing on patient privacy, employing advanced technologies to protect individual data. The company's goal is to enhance understanding of diseases and human behaviors, ultimately contributing to the development of cures in healthcare.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Simplify's Take
What believers are saying
- IQVIA's Med-R1 8B LLM enhances clinical data interpretation for healthcare professionals.
- Recognition in IDC MarketScape boosts IQVIA's credibility in decentralized clinical trials.
- Site Lab Navigator streamlines lab workflows, transforming clinical trial processes.
What critics are saying
- CAR T-cell therapy access disparities may affect IQVIA's reputation.
- Competition in AI models could impact Med-R1 8B's market share.
- Existing lab automation solutions challenge Site Lab Navigator's adoption.
What makes IQVIA unique
- IQVIA's Connected Intelligence™ offers rapid insights for healthcare innovation.
- The company excels in protecting patient privacy with advanced technologies.
- IQVIA's global presence spans over 100 countries with 86,000 employees.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Company News
NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FORCAR T-CELL THERAPY ACROSS EUROPEStockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy as low as 11% for eligible patients. The independent research ‘Achieving CAR T-Cell Therapy Health System Readiness: An assessment of barriers and opportunities’ by the IQVIA Institute for Human Data Science, funded by Gilead and Kite, highlights challenges across countries that can lead to uneven access to CAR T-cell therapy. The report, which assessed seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), found that factors such as complex referral pathways, limited treatment centers and reimbursement challenges are hindering access to this potentially life-saving treatment for eligible patients."CAR T-cell therapy, a potentially curative treatment that has been available since 2017, has transformed the lives of thousands of people worldwide," says Murray Aitken, Executive Director, IQVIA Institute for Human Data Science. "Despite the progress, access barriers still remain for patients eligible for CAR T-cell therapy, leading to worrying inequities in care across Europe. The Institute’s report stresses the need for policy action to address these disparities, help people access this innovative treatment and improve patient outcomes."The IQVIA Institute shares key policy recommendations to support equitable patient access across healthcare systems. These include:1Establish standardised governance systems to coordinate care between referring and treating centres: Patient referrals continue to be a major challenge across countries, with 61% of referring physicians in Spain citing this as a main barrier to treatment.Develop plans to regularly monitor progress and timely access to CAR T-cell therapy: Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%.Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%
LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ - Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments.
IQVIA has launched Med-R1 8B, a medical reasoning large language model (LLM) designed to assist healthcare professionals in interpreting complex clinical data and scientific literature.
COLLEGE PARK, Md., March 26, 2025 /PRNewswire/ -- Registration is open for "Business of Life Sciences and Healthcare for Leaders" (B-LSHC) — an immersive five-day program focused on leadership development and honing critical-thinking and problem-solving skills in medical product development presented by Smith Executive Education at the University of Maryland's Robert H. Smith School of Business.The in-person program takes place June 23-27, 2025, at Van Munching Hall on UMD's College Park campus and is designed for mid-to-advanced career professionals in the LSHC ecosystem including pharmaceutical, biotech and medical device industries; health policy; patient advocacy; regulators; investors; and leaders across medical and regulatory fields.Program sessions will begin at 8:30 a.m. each day "and end with a luminary keynote speaker who will inspire and challenge participants to think outside the box toward the goals of creating innovative solutions for some of our most challenging problems in the LSHC ecosystem," says Wendy Sanhai, PhD, professor of the practice in management and organization for the Smith School and one of the workshop's organizers.Participants will learn from world-renowned faculty, regulatory experts and industry leaders on how to make informed decisions at crucial stages of medical product (drugs, biologics and medical devices) development – from R&D and regulatory submission to commercial launch and reimbursement. And, through expert-led sessions, dynamic capstone project discussions and case-study analysis, participants will sharpen their problem-solving and critical-thinking skills as they expand their professional network.Instructors, in addition to Sanhai, will include UMD and Smith faculty experts Balaji Padmanabhan, director of Smith's Center for Artificial Intelligence in Business; management and organization professors Jennifer Carson Marr, Oliver Schlake and Subra Tangirala; marketing professor Judy Frels; School of Public Health Dean Boris Lushniak; and School of Pharmacy Professor Joga Gobburu.The UMD experts will be joined by leading industry experts including former CEO of Scorpion Therapeutics Axel Hoos, IntoValue CEO Marion Couch, Deloitte Principals Juergen Klenk, Candy Lurken and Mathias Cousin; Euclidean Life Science Advisors President Kenneth Moch; Licensing IP negotiator Steve Ferguson; leaders from IQVIA and former FDA leaders.Participants will:Sharpen problem-solving, leadership and critical-thinking skillsCultivate holistic thinking and multidisciplinary approaches for real-world problems in the LSHC ecosystemBuild upon lessons learned and best practices from regulatory experts, industry luminaries and academic leadersExpand their professional networkIdentify major milestones, potential challenges, risks and mitigation strategies across medical product development pathways in R&D, regulatory submission, product launch and commercializationExecute critical steps in license negotiations and technology transfer processesParticipants should have at least a bachelor's degree and five years of working experience in any LSHC field.Scholarships are available, including for nonprofits, government professionals and veterans. Discounts are available for organizations with multiple participants. Information sessions via Zoom are set for 1-2 p.m
IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the "Leaders" category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment.